Research programme: GPR119 protein agonists - Metabolex
Latest Information Update: 20 Dec 2013
At a glance
- Originator Metabolex
- Developer CymaBay Therapeutics
- Class Small molecules
- Mechanism of Action GPR119 protein agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Type 2 diabetes mellitus